Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 3Neuroblastoma 2Meningioma 2Medulloblastoma 2Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1

Interventions

Cyclophosphamide 35Temozolomide 33Filgrastim 26Etoposide 26Carboplatin 25Vincristine 22Cisplatin 22Radiotherapy 20Magnetic Resonance Spectroscopy 18Thiotepa 14Irinotecan 13Granulocyte Colony-Stimulating Factor 12Peripheral Blood Stem Cell Transplantation 11Lomustine 11Specimen Handling 9Radiation 9Melphalan 9etoposide phosphate 8Topotecan 8Methotrexate 8X-Rays 7Platinum 7Phantoms, Imaging 7sonidegib 6Biopsy 61,2-diaminocyclohexaneplatinum II citrate 6sargramostim 5palbociclib 5Nuclear Medicine Department, Hospital 5HhAntag691 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Medulloblastoma × arginyllysine × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

University of Iowa

Phase 2 Withdrawn
CNS

Medulloblastoma, Meningioma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡